Biotechnology: Regeneron Pharmaceuticals, Inc. owns the largest revenue base; Ascendis Pharma A/S has the fastest current growth.
The industry itself · before any single company
How has Biotechnology moved against S&P 500?
The line below covers 5.2 years. Over the most recent two of them this industry is 100% ahead of S&P 500. Earnings across its companies fell 7% on average over the last four reported quarters. It has been ahead of S&P 500 on a rolling three-month view for 6 weeks running.
BREAKING OUT · ahead 6w~Price up, without the fundamentals confirming138 of 292 companies ahead of S&P 500 by 5% or more over three months2 are 20% or more behind over a year while earnings grew 20% or more
Biotechnology, equal-weighted, based at 200S&P 500, same base, same starttrailing 12-month earnings per share risingfalling
Strength anatomyMixedHow much of the industry is participating, how recently, and whether the movers score well.
Together138 of 292 stocks moving
Fresh38 crossed in the last 4 weeks
Backed by scoresmovers score +2 vs the industry average
Down the cap ladder — bar is now, tick is four weeks ago
Large44/59+9
Mid59/102+8
Small35/131−12
Participation is not spreading downward this month; the larger companies are still carrying most of it.
Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 292 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
Sector relative strength · before individual stocks
Is Biotechnology outperforming S&P 500?
Biotechnology has outperformed S&P 500 by 48.6% over the last 52 weeks. Over 13 weeks the gap is a lead of 17%. 22 of 29 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Revolution Medicines, Inc. is the strongest against the sector itself at +49.8%.
+17.0%Sector vs S&P 500 · 13 weeks
+48.6%Sector vs S&P 500 · 52 weeks
22/29Stocks leading S&P 500
12/29Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Biotechnology has outperformed S&P 500 by 48.6% over 52 weeks and 17% over 13 weeks. 22 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 12 of 29 beat the sector itself. Regeneron Pharmaceuticals, Inc. leads with revenue of $14,919 million, based on 24 of 30 comparable companies through Mar 2026.
Is the Biotechnology sector outperforming S&P 500?
Biotechnology has outperformed S&P 500 by 48.6% over 52 weeks and 17% over 13 weeks. 22 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 12 of 29 beat the sector itself.
Which Biotechnology company is largest by revenue?
Regeneron Pharmaceuticals, Inc. leads with revenue of $14,919 million, based on 24 of 30 comparable companies through Mar 2026.
Which Biotechnology company is growing fastest?
Ascendis Pharma A/S has the fastest current revenue growth at 100%, across 23 of 30 comparable companies.
Which Biotechnology company has the strongest 4-Factor Sector Score?
Incyte Corporation ranks first at 68.9/100 with 72% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Biotechnology company reports the most CAPEX?
Regeneron Pharmaceuticals, Inc. reports the largest latest CAPEX at $231 million, with 28 of 30 companies comparable.
Which Biotechnology company has the least gross debt?
ABIVAX Société Anonyme has the lowest comparable gross debt at $1 million. Royalty Pharma plc has the highest at $8,956 million.
Which Biotechnology company has the lowest comparable PEG?
Genmab A/S has the lowest comparable Guarded PEG at 0.24, among 9 of 30 companies that pass the metric’s comparability rules.
How much history does this Biotechnology comparison include?
The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Companies
30
complete canonical membership
Combined market value
$741.1B
Vertex Pharmaceuticals Incorporated
Revenue growing
20/23
positive TTM year-on-year growth
Beating S&P 500
22/29
positive Mansfield relative strength
Global company selection
00 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Incyte Corporation has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 72% evidence confidence.
Royalty Pharma plc looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Royalty Pharma plc has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.
Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is 10.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -40.4% and the one-year return is -28.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -44.7% and the one-year return is -4.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12.5/35Growth & earnings
Revenue — · PAT — · OPM change —
33% evidence
17.7/25Capital efficiency
ROCE 48.3% · debt/equity 0.03×
68% evidence
10.0/20Valuation
P/E — · PEG —
0% evidence
1.0/20Relative strength
RS sector -47.5% · RS bench -36.1% · 1Y -53.6%
100% evidence
01 · compare level, then change
Revenue Scale & Growth Durability
Regeneron Pharmaceuticals, Inc. has the highest Revenue among the 30 Biotechnology companies compared here, at $14,919 million. Vertex Pharmaceuticals Incorporated is next at $12,218 million. Ascendis Pharma A/S has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies. Its Revenue series carries 19 reported observations across the 20-quarter window.
What the numbers say: Regeneron Pharmaceuticals, Inc. is the scale leader at $14,919 million, 22.1% ahead of Vertex Pharmaceuticals Incorporated. Ascendis Pharma A/S's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 135% from a $867 million base, with 19 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderRegeneron Pharmaceuticals, Inc. · $14,919 million
Gap22.1% versus #2 · Vertex Pharmaceuticals Incorporated
Persistence7/8 recent comparable periods
Coverage24/30 companies · 472 observations
Investor read: Regeneron Pharmaceuticals, Inc. is the scale benchmark; Ascendis Pharma A/S is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Regeneron Pharmaceuticals, Inc.'s growth falls below Ascendis Pharma A/S's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Regeneron Pharmaceuticals, Inc. REGN$14.9B
2Vertex Pharmaceuticals Incorporated VRTX$12.2B
3BeOne Medicines AG ONC$5.7B
4Incyte Corporation INCY$5.4B
5Jazz Pharmaceuticals plc JAZZ$4.4B
Revenue growthfastest growers
1Ascendis Pharma A/S ASND100%
2BridgeBio Pharma, Inc. BBIO100%
3Cytokinetics, Incorporated CYTK100%
4Insmed Incorporated INSM100%
5Madrigal Pharmaceuticals, Inc. MDGL100%
Revenue · company comparison
24/30 level · 23/30 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Royalty Pharma plc has the highest OPM among the 30 Biotechnology companies compared here, at 89.3%. Halozyme Therapeutics, Inc. is next at 49%. Roivant Sciences Ltd. has the highest Margin change at +20242.2 percentage points, so level and change sit with different companies. 24 of 30 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Royalty Pharma plc leads opm at 89.3%; Roivant Sciences Ltd. leads margin change at +20242.2 percentage points.
LeaderRoyalty Pharma plc · 89.3%
Gap82.2% versus #2 · Halozyme Therapeutics, Inc.
Persistence4/8 recent comparable periods
Coverage24/30 companies · 403 observations
Investor read: Royalty Pharma plc sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Royalty Pharma plc RPRX89%
2Halozyme Therapeutics, Inc. HALO49%
3Krystal Biotech, Inc. KRYS46%
4Exelixis, Inc. EXEL41%
5Vertex Pharmaceuticals Incorporated VRTX38%
Margin changefastest expanders
1Roivant Sciences Ltd. ROIV+20,242.2 pp
2Cytokinetics, Incorporated CYTK+8,907.6 pp
3Moderna, Inc. MRNA+615.4 pp
4ABIVAX Société Anonyme ABVX+564.8 pp
5Insmed Incorporated INSM+217.2 pp
Operating margin · company comparison
24/30 level · 27/30 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Regeneron Pharmaceuticals, Inc. has the highest Net profit among the 30 Biotechnology companies compared here, at $4,424 million. Vertex Pharmaceuticals Incorporated is next at $4,338 million. Incyte Corporation has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Regeneron Pharmaceuticals, Inc. leads with $4,424 million of TTM profit, 2% above Vertex Pharmaceuticals Incorporated. Incyte Corporation shows ≥100% on the scoring scale (7055% uncapped) growth from a $1,431 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderRegeneron Pharmaceuticals, Inc. · $4,424 million
Gap2% versus #2 · Vertex Pharmaceuticals Incorporated
Persistence4/8 recent comparable periods
Coverage27/30 companies · 565 observations
Investor read: Regeneron Pharmaceuticals, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Regeneron Pharmaceuticals, Inc. REGN$4.4B
2Vertex Pharmaceuticals Incorporated VRTX$4.3B
3Incyte Corporation INCY$1.4B
4Royalty Pharma plc RPRX$1.4B
5Genmab A/S GMAB$866M
Profit growthfastest growers
1Incyte Corporation INCY100%
2Krystal Biotech, Inc. KRYS81%
3Regeneron Pharmaceuticals, Inc. REGN-1.7%
4Bio-Techne Corporation TECH-18%
5Genmab A/S GMAB-20%
Net profit · company comparison
27/30 level · 9/30 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 20 companies with a series here. The remaining 8 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Regeneron Pharmaceuticals, Inc. has the highest CAPEX among the 30 Biotechnology companies compared here, at $231 million. Vertex Pharmaceuticals Incorporated is next at $133 million. Revolution Medicines, Inc. has the highest CAPEX intensity at 200%, so level and change sit with different companies. 28 of 30 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Regeneron Pharmaceuticals, Inc. reports $231 million of CAPEX; Revolution Medicines, Inc. has the highest covered intensity at 200%. Coverage is only 28 of 30 companies and 499 reported observations, so this is partial evidence—not a complete sector rank.
LeaderRegeneron Pharmaceuticals, Inc. · $231 million
Gap73.7% versus #2 · Vertex Pharmaceuticals Incorporated
Persistence8/8 recent comparable periods
Coverage28/30 companies · 499 observations
Investor read: Use the CAPEX rank as a diligence queue. Verify commissioning, utilization, cash conversion and post-investment ROCE before treating spend as value creation.
This conclusion weakens if: CAPEX rises without higher utilization, operating cash flow or incremental returns.
CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.
CAPEXlargest spenders
1Regeneron Pharmaceuticals, Inc. REGN$231M
2Vertex Pharmaceuticals Incorporated VRTX$133M
3Moderna, Inc. MRNA$62M
4BioNTech SE BNTX$57M
5BeOne Medicines AG ONC$41M
CAPEX intensityhighest reinvestment intensity
1Revolution Medicines, Inc. RVMD200%
2BioNTech SE BNTX38%
3Roivant Sciences Ltd. ROIV33%
4Cytokinetics, Incorporated CYTK32%
5Moderna, Inc. MRNA16%
Capital expenditure · company comparison
28/30 level · 26/30 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Capacity base is net fixed assets plus capital work in progress, straight off the reported balance sheet. It is not cash spent, so it answers a narrower question than CAPEX — but it is reported for companies whose cash-flow CAPEX is not published, which is why it leads here. Missing years remain blank; annual values are never relabelled as quarters.
Full annual capacity base, operating cash flow, CAPEX and free cash flow history
Capacity base · net fixed assets + CWIP · fiscal-year history
Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
ABIVAX Société Anonyme has the lowest Gross debt among the 30 Biotechnology companies compared here, at $1 million. Apogee Therapeutics, Inc. is next at $8 million. BioNTech SE has the lowest Net debt at $14,336 million net cash, so level and change sit with different companies. 29 of 30 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: BioNTech SE has the clearest covered balance-sheet capacity with $14,336 million net cash and gross debt of $303 million. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.
LeaderABIVAX Société Anonyme · $1 million
Gap87.5% versus #2 · Apogee Therapeutics, Inc.
Persistence7/8 recent comparable periods
Coverage29/30 companies · 542 observations
Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.
This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.
Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.
Gross debtlowest gross debt
1ABIVAX Société Anonyme ABVX$1M
2Apogee Therapeutics, Inc. APGE$8M
3Krystal Biotech, Inc. KRYS$9M
4Corcept Therapeutics Incorporated CORT$10M
5Summit Therapeutics Inc. SMMT$20M
Net debtlowest net debt
1BioNTech SE BNTX$-14.3B
2Regeneron Pharmaceuticals, Inc. REGN$-6.0B
3Vertex Pharmaceuticals Incorporated VRTX$-5.3B
4argenx SE ARGX$-5.1B
5Roivant Sciences Ltd. ROIV$-4.2B
Debt and balance-sheet capacity · company comparison
29/30 level · 29/30 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Summit Therapeutics Inc. has the highest ROCE among the 30 Biotechnology companies compared here, at 48.3%. Exelixis, Inc. is next at 10.8%. Ascendis Pharma A/S has the highest ROCE change at +120.8 percentage points, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Summit Therapeutics Inc. leads ROCE at 48.3%, 37.5 percentage points above Exelixis, Inc.. Ascendis Pharma A/S has the strongest latest improvement at +120.8 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderSummit Therapeutics Inc. · 48.3%
Gap347.2% versus #2 · Exelixis, Inc.
Persistence6/8 recent comparable periods
Coverage30/30 companies · 563 observations
Investor read: Summit Therapeutics Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Summit Therapeutics Inc. SMMT48%
2Exelixis, Inc. EXEL11%
3Halozyme Therapeutics, Inc. HALO8.5%
4Alnylam Pharmaceuticals, Inc. ALNY7.8%
5Roivant Sciences Ltd. ROIV7.8%
ROCE changefastest improvers
1Ascendis Pharma A/S ASND+120.8 pp
2ABIVAX Société Anonyme ABVX+14.9 pp
3Roivant Sciences Ltd. ROIV+12.5 pp
4Insmed Incorporated INSM+12.2 pp
5Alnylam Pharmaceuticals, Inc. ALNY+7.2 pp
Return on capital · company comparison
30/30 level · 30/30 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Genmab A/S has the lowest Guarded PEG among the 30 Biotechnology companies compared here, at 0.24×. Halozyme Therapeutics, Inc. is next at 0.27×. Roivant Sciences Ltd. has the lowest P/E at 2.04×, so level and change sit with different companies. 9 of 30 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Genmab A/S has the lowest comparable Guarded PEG at 0.24×, 11.1% below Halozyme Therapeutics, Inc.. Only 9 of 30 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderGenmab A/S · 0.24×
Gap11.1% versus #2 · Halozyme Therapeutics, Inc.
Persistence0/8 recent comparable periods
Coverage9/30 companies · 35 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.
Guarded PEGlowest PEG
1Genmab A/S GMAB0.2
2Halozyme Therapeutics, Inc. HALO0.3
3Royalty Pharma plc RPRX0.3
4Jazz Pharmaceuticals plc JAZZ0.3
5Krystal Biotech, Inc. KRYS0.8
P/Elowest P/E
1Roivant Sciences Ltd. ROIV2.0
2Incyte Corporation INCY13.3
3Exelixis, Inc. EXEL14.0
4Jazz Pharmaceuticals plc JAZZ16.6
5Regeneron Pharmaceuticals, Inc. REGN18.8
Valuation · company comparison
9/30 level · 20/30 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Showing the 12 largest of 20 companies with a series here. The remaining 8 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Roivant Sciences Ltd. has the lowest EV/EBITDA among the 30 Biotechnology companies compared here, at 0.79×. BioNTech SE is next at 7.29×. BioNTech SE has the lowest P/BV at 1.04×, so level and change sit with different companies. 20 of 30 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Roivant Sciences Ltd. leads ev/ebitda at 0.79×; BioNTech SE leads p/bv at 1.04×.
LeaderRoivant Sciences Ltd. · 0.79×
Gap89.2% versus #2 · BioNTech SE
Persistence0/8 recent comparable periods
Coverage20/30 companies · 252 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.
EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.
EV/EBITDAlowest EV/EBITDA
1Roivant Sciences Ltd. ROIV0.8
2BioNTech SE BNTX7.3
3Incyte Corporation INCY8.7
4Exelixis, Inc. EXEL10.9
5Summit Therapeutics Inc. SMMT12.4
P/BVlowest P/BV
1BioNTech SE BNTX1.0
2BioMarin Pharmaceutical Inc. BMRN1.8
3Jazz Pharmaceuticals plc JAZZ2.6
4Regeneron Pharmaceuticals, Inc. REGN2.6
5Moderna, Inc. MRNA2.7
Enterprise and book valuation · company comparison
20/30 level · 28/30 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Showing the 12 largest of 20 companies with a series here. The remaining 8 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Arrowhead Pharmaceuticals, Inc. has the strongest one-year price move in Biotechnology at +438.5%. Revolution Medicines, Inc. leads on Mansfield relative strength against the S&P 500 at +71.7%. 22 of 29 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-07-28.
Every price line is indexed to 100 over the chosen window. Mansfield relative strength compares a price ratio with its own 52-week average; zero separates leadership from lagging.
Price and relative strength
Price is rebased to 100 inside the selected window. Pair ratio rebases each selected company against one chosen denominator.
Before the conclusion · check the blind spots
What can make this comparison misleading?
This Biotechnology comparison names 4 specific ways its own evidence can mislead, all listed below. All 30 companies here report on comparable dates, so no rank carries a stale marker. A high growth rate can still be a low-base artefact.
Keep these limits visible
A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
10 · the complete set
Which companies are included?
All 30 companies in the canonical Biotechnology membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. The charts above default to a selective view; this register is the complete set, with each company's own latest reporting date beside it.
AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.
This comparison is built from the reported filings of 30 Biotechnology companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-28. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-07-28 · weekly price and relative-strength history
Derived metricsGrowth, changes, CAPEX intensity, net debt, guarded PEG and P/BV÷ROE are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
These 18 answers restate the Biotechnology comparison above in question form. Every one is computed from the same 30 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-28. Nothing here is estimated, and none of it is a recommendation.
Which Biotechnology company is the biggest?
Regeneron Pharmaceuticals, Inc. is the largest, with trailing-twelve-month revenue of $14,919 million, ahead of Vertex Pharmaceuticals Incorporated at $12,218 million. That covers 24 of 30 companies with comparable reporting through Mar 2026.
Which Biotechnology company is growing fastest?
Ascendis Pharma A/S has the fastest revenue growth at 100% year on year, across 23 of 30 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.
Which Biotechnology company has the best profit margins?
Royalty Pharma plc has the highest operating margin at 89.3%, from 24 of 30 comparable companies. Roivant Sciences Ltd. shows the biggest recent improvement, at +20242.2 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Biotechnology company makes the most profit?
Regeneron Pharmaceuticals, Inc. earns the most, at $4,424 million of trailing-twelve-month net profit, from 27 of 30 comparable companies. Incyte Corporation has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Biotechnology company earns the highest return on capital?
Summit Therapeutics Inc. leads on return on capital employed at 48.3%, across 30 of 30 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Biotechnology stock is the cheapest?
On guarded PEG — where a LOWER number is cheaper — Genmab A/S screens cheapest at 0.24×. Only 9 of 30 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Which Biotechnology company has the strongest balance sheet?
ABIVAX Société Anonyme carries the lowest comparable gross debt at $1 million, from 29 of 30 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.
Which Biotechnology company is investing most in new capacity?
Regeneron Pharmaceuticals, Inc. reports the largest capital spending at $231 million, across 28 of 30 companies. Spending consumes cash before it earns anything, so treat the ranking as a diligence queue: check commissioning, utilisation and the return earned on the completed assets before reading spend as value creation.
Is the Biotechnology sector beating the market?
Biotechnology has outperformed S&P 500 by 48.6% over the last 52 weeks and 17% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 22 of 29 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Biotechnology stock has the strongest price momentum?
Revolution Medicines, Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Biotechnology company scores highest for research priority?
Incyte Corporation scores 68.9 out of 100 with 72% evidence confidence, from 24.8 points on growth and earnings, 17.1 on capital efficiency, 11.3 on valuation and 15.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Biotechnology companies does this comparison cover, and over what period?
It compares 30 listed companies over up to 20 reported quarters of fundamentals and 6 fiscal years of capital allocation, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Biotechnology sector?
The 30 Biotechnology companies on this page carry $741,130 million of combined market value. Vertex Pharmaceuticals Incorporated is the largest at $124,464 million, about 17% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-28.
What is the Biotechnology sector's P/E ratio?
The median price-to-earnings ratio across the 30 Biotechnology companies on this page is 34.5×, measured on the 20 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-07-28.
How is the Biotechnology sector performing?
22 of the 29 covered Biotechnology companies are beating S&P 500 on Mansfield relative strength. The sector itself is 48.6% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-07-28.
How many Biotechnology stocks are listed in the US?
This comparison covers 30 listed Biotechnology companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.